| Literature DB >> 29875655 |
Vinay Lanke1, S T R Moolamalla1, Dipanjan Roy2, P K Vinod1.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder contributing to rapid decline in cognitive function and ultimately dementia. Most cases of AD occur in elderly and later years. There is a growing need for understanding the relationship between aging and AD to identify shared and unique hallmarks associated with the disease in a region and cell-type specific manner. Although genomic studies on AD have been performed extensively, the molecular mechanism of disease progression is still not clear. The major objective of our study is to obtain a higher-order network-level understanding of aging and AD, and their relationship using the hippocampal gene expression profiles of young (20-50 years), aging (70-99 years), and AD (70-99 years). The hippocampus is vulnerable to damage at early stages of AD and altered neurogenesis in the hippocampus is linked to the onset of AD. We combined the weighted gene co-expression network and weighted protein-protein interaction network-level approaches to study the transition from young to aging to AD. The network analysis revealed the organization of co-expression network into functional modules that are cell-type specific in aging and AD. We found that modules associated with astrocytes, endothelial cells and microglial cells are upregulated and significantly correlate with both aging and AD. The modules associated with neurons, mitochondria and endoplasmic reticulum are downregulated and significantly correlate with AD than aging. The oligodendrocytes module does not show significant correlation with neither aging nor disease. Further, we identified aging- and AD-specific interactions/subnetworks by integrating the gene expression with a human protein-protein interaction network. We found dysregulation of genes encoding protein kinases (FYN, SYK, SRC, PKC, MAPK1, ephrin receptors) and transcription factors (FOS, STAT3, CEBPB, MYC, NFKβ, and EGR1) in AD. Further, we found genes that encode proteins with neuroprotective function (14-3-3 proteins, PIN1, ATXN1, BDNF, VEGFA) to be part of the downregulated AD subnetwork. Our study highlights that simultaneously analyzing aging and AD will help to understand the pre-clinical and clinical phase of AD and aid in developing the treatment strategies.Entities:
Keywords: PPI network; aging; co-expression network; glial cells; graph theory; hippocampus; neurodegenerative disease
Year: 2018 PMID: 29875655 PMCID: PMC5974201 DOI: 10.3389/fnagi.2018.00153
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750
The overlap between cell-type specific genes and modules.
| Module | Astrocytes | Endothelial | Microglia | Neurons | Oligodendrocytes |
|---|---|---|---|---|---|
| M1 | 1.0 | 0.998 | 1.0 | 1.0 | |
| M2 | 0.99 | 0.667 | 1.0 | 1.0 | 0.95 |
| M3 | 0.244 | 1.0 | 1.0 | 1.0 | |
| M4 | 0.998 | 0.489 | 1.0 | 1.0 | |
| M5 | 0.489 | 1.0 | 0.989 | ||
| M6 | 0.723 | 0.292 | 0.496 | 0.99 | 1.0 |
| M7 | 0.949 | 1.0 | 1.0 | 0.897 | 1.0 |
| M8 | 0.947 | 0.929 | 0.983 | 0.98 | |
| M9 | 1.0 | 1.0 | 1.0 | 1.0 | |
| M10 | 1.0 | 1.0 | 1.0 | 0.998 | 1.0 |
| M11 | 0.18 | 1.0 | 1.0 | 0.077 | |
| M12 | 0.995 | 1.0 | 1.0 | 1.0 | |
| M13 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| M14 | 1.0 | 0.96 | 1.0 | 1.0 | 1.0 |
Enrichment of Gene Ontology (GO) terms and KEGG pathways associated with aging and AD-specific modules.
| Module (genes) | KEGG pathway | Biological process | Cellular components | Hub genes |
|---|---|---|---|---|
| M2 (2072) | Ribosome (1.7E-10), Spliceosome (1.2E-2), RNA transport (2.4E-4∗) | rRNA processing (2.4E-13), mRNA splicing (3.6E-5), mRNA processing (1.1E-4) | Nucleolus (1.6E-10), Ribosome (4.1E-6) | TFEB, PAN2, ARHGAP17 |
| M3 (675) | Fatty acid degradation (8.2E-3), Hippo signaling (2.7E-2), PPAR signaling (9.7E-4∗) | Cell adhesion (4.1E-2), Oxidation–reduction process (3.0E-4∗), Fatty acid beta-oxidation (8.5E-4∗) | Extracellular exosome (1.5E-2), Focal adhesion (3.9E-4∗), Extracellular space (8.9E-4∗) | CDC42EP4, EZR, ARHGEF26, TCF7L1, SOX9, ARHGEF6 |
| M4 (701) | Phagosome (4.3E-8), Toll-like receptor signaling (3.1E-6), Cytokine–cytokine receptor interaction (2.7E-4) | Inflammatory response (1.4E-18), Signal transduction (4.0E-12), Toll-like receptor signaling (7.6E-8) | MHC class II protein complex (1.8E-6), Integral component of membrane (2.6E-3), Phagocytic vesicle membrane (4.3E-3) | TYROBP, TREM2, ITGB2, MYO1F, C1Qs, TGFB1 |
| M5 (798) | TNF signaling (1.9E-6), Complement and coagulation cascades (5.6E-5), HIF-1 signaling (4.1E-4) | Inflammatory response (4.8E-16), Response to LPS (1.5E-8), Cellular response to TNF (2.2E-8) | Extracellular matrix (3.5E-7), Extracellular exosome (5.8E-7), MHC class 1 complex (1.4E-4) | TNFRSF1A, MSN, CLIC1, IFITM2 |
| M7 (333) | ECM-receptor interaction (6.4E-3∗), Focal adhesion (3.6E-2∗) | Outer dynein arm assembly (6.4E-12), Inner dynein arm assembly (3.8E-9), Cilium morphogenesis (9.0E-9) | Axoneme (1.3E-18), Motile cilium (5.5E-17) | ZMYND10, ARMC3, CFAP43 |
| M8 (695) | Axon guidance (5.9E-3), Oxytocin signaling (1.6E-3∗), Rap1 signaling (4.8E-3∗) | Calcium ion transport (8.1E-3∗), Potassium ion transport (9.9E-3∗), Dendritic spine morphogenesis (1.1E-2∗) | Cell junction (9.7E-9), Postsynaptic density (6.4E-8), Dendritic spine (9.1E-5) | ICAM5, PRKCG, JPH3, SPTBN2 |
| M9 (2377) | Synaptic vesicle (8.3E-10), Glutamatergic synapse (3.8E-5), Long term potentiation (4.2E-3) | Chemical synaptic transmission (2.3E-16), Neurotransmitter secretion (1.5E-6), Nervous system development (5.8E-5) | Neuron projection (2.5E-10), Dendrite (1.9E-10), Axon (4.9E-9) | UCHL1, STMN2, SYN1, SYT5, SNAP91, PAK3 |
| M10 (2660) | Oxidative phosphorylation (1.8E-19), Proteasome (6.6E-11), Spliceosome (7.5E-7), Protein processing in ER (3.8E-5) | Mitochondria electron transport (1.4E-12), Protein folding (9.3E-9) | Mitochondrion (2.4E-62), Mitochondrial matrix (2.4E-19), Proteasome complex (3.4E-9), Ribosome (2.5E-8) | NDUFAB1, VDAC3, ATP5G3, COPS4, RTCA, POP4 |
| M12 (584) | Retrograde endocannabinoid signaling (4.8E-4), Circadian entrainment (7.1E-3), Glutamatergic synapse (7.2E-3), GABAergic synapse (2.9E-2) | Peptidyl-serine phosphorylation (2.9E-4∗), Neuron cell–cell adhesion (2.1E-3∗) | Postsynaptic density (3.5E-2), Postsynaptic membrane (2.9E-2) | YWHAZ, GADP1, SYNJ1, MAPK9, G3BP2, ATP6AP2 |
Module hub genes in aging and AD.
| Gene | Role/function | Reference |
|---|---|---|
| TFEB | Involved in Aβ-induced pathogenesis of AD by regulating the autophagy-lysosome pathway | |
| EZR | Role in immune synapse along with MSN | |
| TCF7L1 | Mediates Wnt signaling pathway; Altered in AD patients in the hippocampus | |
| SOX9 | Glial fate specification | |
| TYROBP | Activates immune response; genetic variants are risk factor for AD | |
| TREM2 | Activates immune response; genetic variants are risk factor for AD | |
| C1Qs | Associated with early synaptic loss in AD mice models | |
| TGFB1 | Major role in the activation of microglia | |
| ITGB2 | Identified as one of key inflammatory gene in AD mice models | |
| MSN | Role in immune synapse along with EZR; identified as highly expressed in the AD brain using proteomic analysis | |
| CLIC1 | Identified as highly expressed in the AD brain using proteomic analysis; involved in Aβ induced generation of ROS | |
| IFITM2 | Identified as part of microglial sensome in aging with neuroprotective role | |
| TNFRSF1A | Identified as AD associated gene using genome wide haplotype association study | |
| UCHL1 | Regulates the production of Aβ by interacting with APP | |
| SNAP91 | Role in vesicle mediated transport; downregulated in AD patients and AD mice models | |
| PAK3 | Reduced activity in AD patients and AD mice models | |
| NDUFAB1 | Role in energy metabolism; downregulated in AD | |
| YWHAZ | Identified as AD biomarker using proteomic analysis; reported as hub gene in aging and AD | |
| SYNJ1 | Accelerate Aβ clearance and attenuates cognitive deterioration | |
| ATP6AP2 | Downregulation induces neurodegeneration |